306 related articles for article (PubMed ID: 35251352)
1. Cell-based immunotherapy of glioblastoma multiforme.
Bryukhovetskiy I
Oncol Lett; 2022 Apr; 23(4):133. PubMed ID: 35251352
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor-β mimics the key proteome properties of CD133
Bryukhovetskiy I; Shevchenko V; Arnotskaya N; Kushnir T; Pak O; Victor Z; Zaitsev S; Khotimchenko Y; Bryukhovetskiy A; Sharma A; Sharma HS
Int Rev Neurobiol; 2020; 151():219-242. PubMed ID: 32448609
[TBL] [Abstract][Full Text] [Related]
3. Molecular determinants of the interaction between glioblastoma CD133
Shevchenko V; Arnotskaya N; Pak O; Sharma A; Sharma HS; Khotimchenko Y; Bryukhovetskiy A; Bryukhovetskiy I
Int Rev Neurobiol; 2020; 151():155-169. PubMed ID: 32448605
[TBL] [Abstract][Full Text] [Related]
4. Personalized therapy and stem cell transplantation for pro-inflammatory modulation of cancer stem cells microenvironment in glioblastoma: Review.
Bryukhovetskiy I; Pak O; Khotimchenko Y; Bryukhovetskiy A; Sharma A; Sharma HS
Int Rev Neurobiol; 2020; 151():67-98. PubMed ID: 32448615
[TBL] [Abstract][Full Text] [Related]
5. Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma.
Shevchenko V; Arnotskaya N; Korneyko M; Zaytsev S; Khotimchenko Y; Sharma H; Bryukhovetskiy I
Oncol Rep; 2019 May; 41(5):3080-3088. PubMed ID: 30864699
[TBL] [Abstract][Full Text] [Related]
6. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
[TBL] [Abstract][Full Text] [Related]
7. Regulation of cancer stem cells and immunotherapy of glioblastoma (Review).
Kosianova А; Pak O; Bryukhovetskiy I
Biomed Rep; 2024 Feb; 20(2):24. PubMed ID: 38170016
[TBL] [Abstract][Full Text] [Related]
8. Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review).
Bryukhovetskiy I; Ponomarenko A; Lyakhova I; Zaitsev S; Zayats Y; Korneyko M; Eliseikina M; Mischenko P; Shevchenko V; Shanker Sharma H; Sharma A; Khotimchenko Y
Int J Mol Med; 2018 Aug; 42(2):691-702. PubMed ID: 29749540
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic stem cells as a tool for the treatment of glioblastoma multiforme.
Bryukhovetskiy IS; Dyuizen IV; Shevchenko VE; Bryukhovetskiy AS; Mischenko PV; Milkina EV; Khotimchenko YS
Mol Med Rep; 2016 Nov; 14(5):4511-4520. PubMed ID: 27748891
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma: What can we do for these patients today and what will we be able to do in the future?
Bryukhovetskiy I; Kosianova A; Zaitsev S; Pak O; Sharma A; Sharma HS
Prog Brain Res; 2021; 265():99-118. PubMed ID: 34560928
[TBL] [Abstract][Full Text] [Related]
11. Targeting cancer stem cells for treatment of glioblastoma multiforme.
Cho DY; Lin SZ; Yang WK; Lee HC; Hsu DM; Lin HL; Chen CC; Liu CL; Lee WY; Ho LH
Cell Transplant; 2013; 22(4):731-9. PubMed ID: 23594862
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
William D; Walther M; Schneider B; Linnebacher M; Classen CF
PLoS One; 2018; 13(1):e0191511. PubMed ID: 29352318
[TBL] [Abstract][Full Text] [Related]
13. Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors.
Nicholas S; Mathios D; Ruzevick J; Jackson C; Yang I; Lim M
Brain Tumor Res Treat; 2013 Apr; 1(1):2-8. PubMed ID: 24904882
[TBL] [Abstract][Full Text] [Related]
14. Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.
Daniele S; Zappelli E; Natali L; Martini C; Trincavelli ML
Cell Death Dis; 2014 Nov; 5(11):e1539. PubMed ID: 25429616
[TBL] [Abstract][Full Text] [Related]
15. Induction Therapy of Retinoic Acid with a Temozolomide-Loaded Gold Nanoparticle-Associated Ultrasound Effect on Glioblastoma Cancer Stem-Like Colonies.
Fadera S; Chen PY; Liu HL; Lee IC
ACS Appl Mater Interfaces; 2021 Jul; 13(28):32845-32855. PubMed ID: 34235925
[TBL] [Abstract][Full Text] [Related]
16. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
17. TGFβ-Responsive HMOX1 Expression Is Associated with Stemness and Invasion in Glioblastoma Multiforme.
Ghosh D; Ulasov IV; Chen L; Harkins LE; Wallenborg K; Hothi P; Rostad S; Hood L; Cobbs CS
Stem Cells; 2016 Sep; 34(9):2276-89. PubMed ID: 27354342
[TBL] [Abstract][Full Text] [Related]
18. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
19. Enhanced targeting of invasive glioblastoma cells by peptide-functionalized gold nanorods in hydrogel-based 3D cultures.
Gonçalves DPN; Rodriguez RD; Kurth T; Bray LJ; Binner M; Jungnickel C; Gür FN; Poser SW; Schmidt TL; Zahn DRT; Androutsellis-Theotokis A; Schlierf M; Werner C
Acta Biomater; 2017 Aug; 58():12-25. PubMed ID: 28576716
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of the effect of TGF-β1 on U87 human glioblastoma cells.
Bryukhovetskiy I; Shevchenko V
Oncol Lett; 2016 Aug; 12(2):1581-1590. PubMed ID: 27446475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
